PepGen Inc. PEPG
PepGen Inc. (Nasdaq: PEPG) is a rare genetic drug developer. Its lead program, PGN-EDODM1, is in Phase 2 for Myotonic dystrophy type 1 (DM1). Its next catalyst on record is PGN-EDODM1: PepGen expects to report clinical data from the 10 mg/kg multiple-dose cohort of FREEDOM2 in November 2026. (November 2026).
Upcoming catalysts
- November 2026PGN-EDODM1 — PepGen expects to report clinical data from the 10 mg/kg multiple-dose cohort of FREEDOM2 in November 2026.
Company on track to report clinical data from 10 mg/kg multiple dose cohort in November
Next further out: PGN-EDODM1 — Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in the first half of 2027. (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PGN-EDODM1 | DM1 | oligonucleotide-other | Phase 2 |
| PGN-EDO51 | Duchenne muscular dystrophy (DMD) | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Aug 6, 2026n/a DSMB recommended advancing FREEDOM2 into highest 12.5 mg/kg dose cohort and escalating OLE from 5 to 10 mg/kg.
independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study into the third and highest multiple ascending dose cohort of 12.5 mg/kg
Filing - Aug 6, 2026positive PGN-EDODM1 5 mg/kg multiple-dose cohort in FREEDOM2 showed mean splicing correction of 22.9% (excluding outlier) and favorable safety with all adverse events mild or moderate.
PGN-EDODM1 was generally well-tolerated; all AEs were mild or moderate in severity, with no SAEs or cumulative toxicity with repeat dosing observed
Filing - Aug 6, 2026positive Independent DSMB recommended advancing FREEDOM2 into the 12.5 mg/kg cohort and dose escalation in the open-label extension from 5 mg/kg to 10 mg/kg.
an independent Data and Safety Monitoring Board (DSMB) recommended advancing the FREEDOM2 trial into the third and highest dose cohort (12.5 mg/kg).
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.